Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor

• Published in: Human cell : official journal of Human Cell Research Society Vol. 34; no. 1; pp. 254 - 259
• Main Authors: Noguchi, Rei, Yoshimatsu, Yuki, Ono, Takuya, Sei, Akane, Hirabayashi, Kaoru, Ozawa, Iwao, Kikuta, Kazutaka, Kondo, Tadashi
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.01.2021; Springer Nature B.V
• Subjects: Antineoplastic drugs; Antitumor agents; Biomedical and Life Sciences; Cancer; Cell Biology; Cell culture; Cell fusion; Cell Line; Enzyme inhibitors; Fusion protein; Gefitinib; Gynecology; Life Sciences; Mesenchyme; Mitoxantrone; Molecular modelling; Oncology; Reproductive Medicine; Stem Cells; Surgery; Synovium; High-throughput screening; Anticancer drug; Tenosynovial giant cell tumor; TGCT; Patient-derived cell line
• ISSN: 1749-0774; 0914-7470; 1749-0774
• DOI: 10.1007/s13577-020-00425-8

Tenosynovial giant cell tumor (TGCT) is a mesenchymal tumor arising from the synovium of tendon sheath and joints, characterized by translocation t(1;2)(p13;q37). Clinical behaviors of TGCT range from favorable to locally aggressive and further research is required to lead the identification of novel therapeutic avenues for TGCT. Patient-derived cell lines are an indispensable tool for interrogating molecular mechanisms underlying the progression of disease. However, only one TGCT cell line is currently available from cell banks, and a paucity of adequate patient-derived cells hinders basic and translational research. This study aimed to establish a novel cell line of TGCT. To this end, a novel cell line, NCC-TGCT1-C1 was established from the primary tumor tissue of a 40-year-old female patient with TGCT. The cells exhibited translocation t(1;2)(p13;q37), generating COL6A3-CSF1 fusion gene. The cells were maintained as a monolayer culture through more than 30 passages over 12 months. The cells exhibited continuous growth and the ability for spheroid formation and invasion. When used in a high-throughput assay to evaluate the anti-proliferative effects of 164 anticancer drugs, the cells responded strongly to a kinase inhibitor such as gefitinib, and mitoxantrone. Our results indicate that the novel TGCT cell line, designated NCC-TGCT1-C1, was successfully established and could be used to study TGCT development and the effects of anticancer agents.